A lot of investors seem to be quite pessimistic about Pfizer’s (PFE) future. The loss of exclusivity of certain important brands that are coming up are a big reason for this increasing pessimism and cautiousness. And indeed this can cause problems for Pfizer, but this company is more than capable of offsetting these difficulties. The downside these LOEs might cause is not as bad as a lot of investors believe. I do not share the belief that Pfizer’s shares are going to tank anytime soon.
Last quarter appeared to be a disappointing one to many investors as the stock immediately declined after the release. A yoy decline of the revenue while also missing the consensus revenue estimate was enough reason for a lot of investors to sell their shares. But the 1.8% decline yoy can be blamed on a negative impact FOREX had on the quarter vs last year as well as less selling days. This quarter counted 1 selling day less than last year in the US, and two fewer selling days in international markets. But while this would explain the yoy sales decline a lack of revenue growth is still far from desirable.